COVID-19: a trigger for severe thrombotic microangiopathy in a patient with complement gene variant

• Main Authors: Pinte Larisa (Author), Sorohan Bogdan Marian (Author), Prohászka Zoltán (Author), Gherghiceanu Mihaela (Author), Băicuş Cristian (Author)
• Format: Book
• Published: Sciendo, 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2501-062X; 10.2478/rjim-2021-0040
• Keywords: covid-19; thrombotic microangiopathy; acute kidney injury; complement; Internal medicine; RC31-1245
• Source: Romanian Journal of Internal Medicine, Vol 60, Iss 2, Pp 138-142 (2022)

The evidence regarding thrombotic microangiopathy (TMA) related to Coronavirus Infectious Disease 2019 (COVID-19) in patients with complement gene mutations as a cause of acute kidney injury (AKI) are limited. We presented the case of a 23-year-old male patient admitted with an asymptomatic form of COVID-19, but with uncontrolled hypertension and AKI. Kidney biopsy showed severe lesions of TMA. In evolution patient had persistent microangiopathic hemolytic anemia, decreased level of haptoglobin and increased LDH level. Decreased complement C3 level and the presence of schistocytes were found for the first time after biopsy. Kidney function progressively decreased and the patient remained hemodialysis dependent. Complement work-up showed a heterozygous variant with unknown significance in complement factor I (CFI) c.-13G>A, affecting the 5' UTR region of the gene. In addition, the patient was found to be heterozygous for the complement factor H (CFH) H3 haplotype (involving the rare alleles of c.-331C>T, Q672Q and E936D polymorphisms) reported as a risk factor of atypical hemolytic uremic syndrome. This case of AKI associated with severe TMA and secondary hemolytic uremic syndrome highlights the importance of genetic risk modifiers in the alternative pathway dysregulation of the complement in the setting of COVID-19, even in asymptomatic forms.